SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...
MIT researchers have developed an experimental mRNA-based therapy that restored key immune functions lost with age in mice.
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 ...
Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...
A team at RMIT University in Melbourne say that extremely small metal particles – which they dub ‘nanodots’ – could be ...
News-Medical.Net on MSN
New trial aims to improve both survival and quality of life for men with advanced prostate cancer
The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
The one-and-a-half-day symposium will provide an overview of recent advances in the treatment of solid tumors with novel ...
Morning Overview on MSN
1 protein block slowed cancer in mice, and it’s a promising target
Researchers have identified a single protein whose absence can cripple tumors in mice, slowing their growth and in some cases ...
DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...
Explore the potential of polysaccharide microneedles in cancer immunotherapy for effective drug delivery and immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results